The Healthline report on EWG's 2026 findings—that only 550 of 2,784 SPF products meet its five-criteria threshold—correctly flags UVA/UVB balance and photostability shortfalls, yet underplays how EWG's hazard scoring relies on in vitro and animal data rather than human outcomes. No large-scale RCT (sample >10,000) has linked specific U.S.-approved filters to elevated skin cancer incidence; the sole major RCT, Green et al. (1999, n=1,621, Queensland), demonstrated daily SPF 16 reduced squamous cell carcinoma by 40% but was underpowered for melanoma. EWG's stricter limits on oxybenzone and octinoxate echo European bans, yet FDA's 2025 bemotrizinol proposal remains stalled, leaving Americans with 1999-era filters while Asia deploys newer, more photostable molecules. Observational cohorts (e.g., Nurses' Health Study follow-ups) show consistent broad-spectrum use correlates with lower melanoma risk, but suffer from self-report bias and no ingredient-level randomization. Mineral filters like zinc oxide score higher on EWG metrics due to lower systemic absorption, yet no head-to-head RCT compares long-term cancer prevention between mineral and chemical formulations. The overlooked factor is application behavior: even top-rated products fail if users apply <25% of recommended volume, per multiple observational studies. Consumers gain more by selecting any broad-spectrum SPF 30+ they will reapply than by chasing EWG's 20% tier.